ReviewStem cell research & therapy2018
Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials.
Review in Stem cell research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Ethical Implications of Tissue Engineering for Regenerative Purposes: A Systematic Review.Tissue engineering. Part B, Reviews · 2023Pooled it
- Early-Phase Clinical Trials of Bio-Artificial Organ Technology: A Systematic Review of Ethical Issues.Transplant international : official journal of the European Society for Organ Transplantation · 2022Pooled it
- Multidimensional bibliometric analysis and global trends in the nervous system's role in bone regeneration.Regenerative therapy · 2026Article
- The global regulatory landscape of stem cell medical aesthetics: challenges, comparisons, and pathways to coordination.Stem cells translational medicine · 2026Review
- Navigating the Global Regulatory Landscape for Exosome-Based Therapeutics: Challenges, Strategies, and Future Directions.Pharmaceutics · 2025Review
- Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications.Journal of clinical medicine · 2025Review
- Recent advances on 3D-printed PCL-based composite scaffolds for bone tissue engineering.Frontiers in bioengineering and biotechnology · 2023Review
- Navigating regulatory pathways for translation of biologic cartilage repair products.Science translational medicine · 2022Review
- Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.Frontiers in public health · 2021Review
- Assessing the generalisability of a multicentre qualitative dementia research: the experience and challenges faced by the MinD project in Europe.Open research Europe · 2021Article
- Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Xeno-Free Reprogramming of Peripheral Blood Mononuclear Erythroblasts on Laminin-521.Current protocols in stem cell biology · 2020Article
- The Direct to Consumer Stem Cell Market and the Role of Primary Care Providers in Correcting Misinformation.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the context of regenerative medicine and cellular therapies, the treatment under study often targets a less common disease or condition for which recruitment of a large number of research participants at any given site is challenging, if not impossible. One way to overcome this challenge is with a multi-centre clinical trial. This manuscript first aims to briefly outline the existing ethical, legal and social implications as well as the regulatory frameworks associated with multi-centre regenerative medicine clinical trials. Second, it considers the regulatory limitations and barriers surrounding the initiation of such trials in Canada, the USA and Europe. Third, it concludes with a set of recommendations for facilitating multi-centre clinical trials, at both national and international levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.